Interleukin-6 receptor antagonists in patients with severe Covid-19 infection

With the support of the European Union – through FP7-HEALTH-2013-INNOVATION: the emerging platform for European Prevention (Re-) Consortium Epidemics (PREPARE) (602525); and Horizon 2020 research and innovation program: Covid-19 Rapid Emergency Research response consortium (RECOVER) (101003589) – and with the National Health and Medical Research Council of Australia (APP1101719), New Zealand Health Research Council (16/3131) , Canadian Institutes of Health Research Strategy for Patient Research Innovative Clinical Trials Program Award (158584), NIHR UK and Imperial Biomedical Research Center NIHR, Irish Health Research Board (CTN 2014-012), the UPMC Learning While Doing Program, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Consortium for Appropriate Research, and the Wellcome Trust Innovations Project ( 215522). Dr. Gordon is funded by NIHR Research Professor (RP-2015-06-18), and Drs. Shankar-Hari with NIHR Clinical Expert Fellowship (CS-2016-16-011).

Publication forms provided by the authors with the full text of this article can be found at NEJM.org.

The members of the writing committee are as follows: Anthony C. Gordon, MB, BS, MD, Paul R. Mouncey, M.Sc., Farah Al-Bidh, Ph.D., Kathryn M. Rowan, Ph.D. , Alistair D. Nichol, MD, Ph.D., Yaseen M. Arabi, MD, Djillali Annane, MD, Ph.D., Abi Beane, Ph.D., Wilma van Bentum-Puijk, M.Sc., Lindsay R. Berry, Ph.D., Zahra Bhimani, MPH, Marc JM Bonten, MD, Ph.D., Charlotte A. Bradbury, MB, Ch.B., Ph.D., Frank M. Brunkhorst, MD, Ph.D. .D., Adrian Buzgau, M.Sc., Allen C. Cheng, MB, BS, Ph.D., Michelle A. Detry, Ph.D., Eamon J. Duffy, B.Pharm., Lise J. Estcourt , MB, B.Ch., Ph.D., Mark Fitzgerald, Ph.D., Herman Goossens, Ph.D., Rashan Haniffa, Ph.D., Alisa M. Higgins, Ph.D., Thomas E. Hills, Ph.D., Christopher M. Horvat, MD, Francois Lamontagne, MD, Patrick R. Lawler, MD, MPH, Helen L. Leavis, MD, Ph.D., Kelsey M. Linstrum, MS, Edward Litton, MD, Ph.D., Elizabeth Lorenzi, Ph.D., John C. Marshall, MD, Florian B. Mayr, MD, MPH, Daniel F. McAuley, MD, Anna McGlothlin, Ph.D., Shay P. McGuinness , MD, Bryan J. McVerry, MD, Stephanie K. Montgomery, M.Sc., Susan C. Morpeth, MD, Ph.D., Srinivas Murthy, MD, Katrina Orr, B.Pharm., Rachael L. Parke, Ph.D. , Jane C. Parker, BN, Asad E. Patanwala, Pharm.D., MPH, Ville Pettilä, MD, Emma Rademaker, MD, Marlene S. Santos, MD, MSHS, Christina T. Saunders, Ph.D., Christopher W. Seymour, MD, Manu Shankar-Hari, MD, Ph.D., Wendy I. Sligl, MD, Alexis F. Turgeon, MD, Anne M. Turner, MPH, Frank L. van de Veerdonk, MD, Ph.D. D., Ryan Zarychanski, MD, Cameron Green, M.Sc., Roger J. Lewis, MD, Ph.D., Derek C. Angus, MD, MPH, Colin J. McArthur, MD, Scott Berry, Ph.D ., Steve A. Webb, MD, Ph.D., and Lennie PG Derde, MD, Ph.D.

The views expressed in this publication are those of the authors and may not be those of the National Health Service, the National Institute for Health Research (NIHR), or the Department of Health and Social Care.

This article was published on February 25, 2021, at NEJM.org.

A report on data sharing provided by the authors can be found in the full text of this article at NEJM.org.

We thank the staff of the NIHR Clinical Research Network (United Kingdom), the Department of Health Services of the UPMC Health System (United States), and the Direction de la Recherche Clinique et de l’Innovation de l’Assistance Publique – Hôpitaux de Paris (France) for their support of partner recruitment.

Source